Visen Pharmaceuticals is a Shanghai-based biotech focused on developing and commercializing innovative endocrine drugs for patients in Greater China. The company is developing TransCon hGH (lonapegsomatropin), TransCon PTH, and TransCon CNP, and emphasizes a "Patient First" approach. A Phase 3 study of TransCon hGH (lonapegsomatropin) in China is currently ongoing. Visen intends to use the Series B proceeds to accelerate clinical development of its candidates and to build a commercialization foundation in the region. Led by CEO Pony Lu, the company aims to introduce world-leading treatment methods and drugs into the China market. Visen was formed in 2018 by Ascendis Pharma and an investor syndicate to focus on endocrinology therapies across Greater China.

Total raised

$150M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2021